590 Testosterone replacement therapy with testosterone undecanoate long acting intramuscular injections is associated with reduction in obesity

2012 ◽  
Vol 11 (1) ◽  
pp. e590-e590a
Author(s):  
Douaihy Y. El ◽  
A.D.J. Yassin ◽  
R. Pinkhasov ◽  
K. Prawat ◽  
R. Shabsigh ◽  
...  
Keyword(s):  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Testosterone Undecanoate ◽  
Intramuscular Injections ◽  
Long Acting

Correction of Androgen Deficiency in Men with Type 2 Diabetes

2021 ◽  
Vol 16 ◽  
Author(s):  
Volodymyr Pankiv ◽  
Tetyana Yuzvenko ◽  
Nazarii Kobyliak ◽  
Ivan Pankiv
Keyword(s):  
Type 2 Diabetes ◽  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Control Group ◽  
Total Testosterone ◽  
Testosterone Replacement Therapy ◽  
Androgen Deficiency ◽  
Testosterone Undecanoate ◽  
Testosterone Levels

Background: In men with low levels of testosterone in the blood, it is believed that the symptoms can be regarded as an association between testosterone deficiency syndrome and related comorbidities. Aim: to investigate the effectiveness of testosterone therapy in patients with type 2 diabetes (T2D) and androgen deficiency. Materials and methods: Testosterone replacement therapy was carried out in 26 men with T2D and clinically or laboratory-confirmed androgen deficiency. The age of the subjects ranged from 35 to 69 years old. Laboratory studies included determinations of the concentration of the hormones estradiol, luteinizing hormone (LH), and prostate-specific antigen (PSA). The observation period was 9 months. Results: The average level of total blood testosterone in the subjects before treatment was 9.4 mol/l and was likely lower than that of the control group (19.3 ± 1.6 nmol/l). The levels of total testosterone in the subjects ranged from 3.9 nmol/l to 10.7 nmol/l, and hormone levels measuring less than 8.0 nmol/l were observed in only 11 patients. After a course of testosterone replacement therapy, a stabilization in total testosterone levels at the level of reference values (as compared to the start of treatment) was observed in the blood of men with T2D after 9 months of observation and the administration of the fourth injection (16.83 ± 0.75 nmol/l). Conclusion: The use of long-acting injectable testosterone undecanoate leads to normalization of total testosterone levels in the blood of men with T2D and androgen deficiency, and LH levels in these patients are unlikely to change.

scholarly journals Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits

2013 ◽  
Vol 7 (3-4) ◽  
pp. e221-5 ◽  
Author(s):  
Chen Zhao ◽  
Du Geon Moon ◽  
Jong Kwan Park
Keyword(s):  
Cardiovascular Disease ◽  
Replacement Therapy ◽  
Blood Viscosity ◽  
Whole Blood ◽  
Density Lipoprotein ◽  
Plasma Testosterone ◽  
Testosterone Replacement Therapy ◽  
Testosterone Undecanoate ◽  
Whole Blood Viscosity ◽  
Long Acting

Objective: The association between testosterone replacement therapy and cardiovascular risk remains controversial. Blood viscosity is a known individual risk factor for cardiovascular disease mortality. The objective of the present study was to investigate the effects of the long-acting injectable testosterone undecanoate (TU) on risk factors of cardiovascular disease. Methods: Twenty four male New Zealand white rabbits (2.5 kg) were randomly divided into three groups of eight. The first group was used as control. The second group was castrated bilaterally. The third group was administrated with 6 mg/kg of TU at 1 day and 6 weeks after castration. Whole blood viscosity, total plasma testosterone, hemoglobin (Hb), hematocrit (Hct), fibrinogen (FBN), total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C) levels were measured at baseline, 6 weeks and 18 weeks. Results: In control group, whole blood viscosity and FBN were significantly increased at 6 and 18 weeks. Castration significantly increased the levels of TC, TG, HDL-C and LDL-C, but decreased Hct and Hb. In the TU injection group, whole blood viscosity was markedly decreased in all share rates, whereas the FBN level was increased. Hb and Hct showed a tendency for higher concentration at 6 weeks. Conclusions: Long-acting injectable TU provides another reliable treatment option for testosterone replacement therapy. Moreover, the patients may receive additional beneficial effect in lowered whole blood viscosity.

957: PSA & LIPID Dynamics in Hypogonadal Men Treated with Testosterone Replacement Therapy

2007 ◽  
Vol 177 (4S) ◽  
pp. 316-317
Author(s):  
Jay Simhan ◽  
R. Matthew Coward ◽  
Culley C. Carson
Keyword(s):  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy ◽  
Lipid Dynamics

Testosterone Replacement Therapy

2006 ◽  
Vol 39 (13) ◽  
pp. 16
Author(s):  
WILLIAM E. GOLDEN ◽  
ROBERT H. HOPKINS
Keyword(s):  
Replacement Therapy ◽  
Testosterone Replacement ◽  
Testosterone Replacement Therapy
Sign in / Sign up

Export Citation Format

Share Document